Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Renzo Carletti

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
The European Journal of Neuroscience|April 23, 2005
Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophreniaRenzo Carletti, Mauro Corsi, Sergio Melotto, et al.
British Journal of Pharmacology|February 28, 2006
[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brainCristiana Griffante, Renzo Carletti, Filippo Andreetta, et al.
Current Opinion in Pharmacology|August 15, 2017
Receptor distribution studiesRenzo Carletti, Stefano Tacconi, Manolo Mugnaini, et al.
The European Journal of Neuroscience|May 20, 2003
Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brainLaura Caberlotto, Yasmin L Hurd, Paul Murdock, et al.
Bioorganic & Medicinal Chemistry|October 1, 2013
Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidateRomano Di Fabio, Giuseppe Alvaro, Simone Braggio, et al.
Journal of Medicinal Chemistry|October 15, 2010
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disordersMassimo Gianotti, Maurizio Botta, Stephen Brough, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 13, 2022
A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potentialSusan A Greenfield, Gregory M Cole, Clive W Coen, et al.
Journal of Medicinal Chemistry|June 10, 2010
6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitorFabrizio Micheli, Paolo Cavanni, Daniele Andreotti, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
The European Journal of Neuroscience|April 23, 2005
Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophreniaRenzo Carletti, Mauro Corsi, Sergio Melotto, et al.
British Journal of Pharmacology|February 28, 2006
[3H]GR205171 displays similar NK1 receptor binding profile in gerbil and human brainCristiana Griffante, Renzo Carletti, Filippo Andreetta, et al.
Current Opinion in Pharmacology|August 15, 2017
Receptor distribution studiesRenzo Carletti, Stefano Tacconi, Manolo Mugnaini, et al.
The European Journal of Neuroscience|May 20, 2003
Neurokinin 1 receptor and relative abundance of the short and long isoforms in the human brainLaura Caberlotto, Yasmin L Hurd, Paul Murdock, et al.
Bioorganic & Medicinal Chemistry|October 1, 2013
Identification, biological characterization and pharmacophoric analysis of a new potent and selective NK1 receptor antagonist clinical candidateRomano Di Fabio, Giuseppe Alvaro, Simone Braggio, et al.
Journal of Medicinal Chemistry|October 15, 2010
Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disordersMassimo Gianotti, Maurizio Botta, Stephen Brough, et al.
Alzheimer'S & Dementia (New York, N. Y.)|April 13, 2022
A novel process driving Alzheimer's disease validated in a mouse model: Therapeutic potentialSusan A Greenfield, Gregory M Cole, Clive W Coen, et al.
Journal of Medicinal Chemistry|June 10, 2010
6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane: a new potent and selective triple reuptake inhibitorFabrizio Micheli, Paolo Cavanni, Daniele Andreotti, et al.
Pageof 1